INTRODUCTION {#s1}
============

Epilepsy, estimated to affect about 65 million individuals worldwide \[[@R1]\], is a serious neurological disorder syndrome of refractory seizures resulting in devastating effects on patients \[[@R2]\]. Mesial temporal lobe epilepsy with hippocampal sclerosis (mTLE-HS) is the most common type of focal epilepsy, which is characterized by spontaneous recurrent seizures, neuronal cell loss, and mossy fibers sprouting in the hippocampus \[[@R3]--[@R5]\]. Status epilepticus can impair brain function and memory, which is a threat to the lives of patients \[[@R6]\]. At the present, the exact underlying molecular mechanisms of mTLE-HS are still unclear. In addition, accurate diagnosis and timely treatment can achieve good therapeutic effect for epilepsy. Therefore, understanding the pathogenesis of mTLE-HS and improvement of early diagnosis and effective treatments are required.

Exosomes, a specific subtype of secreted membrane vesicles that are approximately 30--100 nm in size, are involved in cell-to-cell communication and targeting cells by transferring exosomal molecules including proteins, mRNAs, and microRNAs (miRNAs) \[[@R7], [@R8]\]. Exosomes are widely distributed in the blood, urine, milk, and other bodily fluids \[[@R9]\]. Exosomal miRNAs have been identified, both in physiological and disease conditions \[[@R9]\]. Furthermore, the quantity and composition of exosomal miRNAs are different between patients and healthy individuals \[[@R10]\]. Exosomal miRNAs are involved in the origin and progress of diseases, such as viral infection, cancer, and central nervous system degenerative diseases \[[@R11], [@R12]\]. Exosomal miRNAs may serve as valuable noninvasive biomarkers for the diagnosis and prognosis of certain diseases, including glioma, Alzheimer\'s disease (AD), and Parkinson\'s disease (PD) \[[@R13], [@R14]\].

There is growing evidence supporting miRNAs changes in the pathophysiology of epilepsy \[[@R1]\]. However, exosomal miRNAs in the plasma of mTLE-HS patients have not yet been investigated. The primary goal of this study was to characterize differences in exosomal miRNAs in plasma from mTLE-HS patients and to further explore their biological functions and clinical significance.

RESULTS {#s2}
=======

MiRNAs were differentially expressed from plasma exosomes in mTLE-HS patients compared with healthy controls {#s2_1}
------------------------------------------------------------------------------------------------------------

First, miRNAs profiles of plasma exosomes from three mTLE-HS patients and gender and age matched three healthy controls were investigated by using Affymetrix miRNA 4.0 Arrays ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}). The microarray results showed the differential expression of 50 exosomal miRNAs in mTLE-HS patients compared to those in healthy controls. Among these, we found that 2 miRNAs were significantly increased and 48 miRNAs were significantly decreased (fold change \> 1.2; *P* \< 0.05) in mTLE-HS patients when compared to healthy controls. Group specific signal intensities of the exosomal miRNAs profile and the volcano plot for the differentially expressed miRNAs between mTLE-HS patients and control healthy are shown in Figure [1A](#F1){ref-type="fig"} and Figure [1B](#F1){ref-type="fig"}, and the information of the 50 miRNAs is listed in Table [1](#T1){ref-type="table"} with fold changes and *P* values.

###### 50 differentially expressed exosomal miRNAs in plasma in mTLE-HS versus controls

  microRNA           Fold-change   Style   *p*-value   rank
  ------------------ ------------- ------- ----------- ------
  hsa-miR-4668-5p    −9.854432     down    0.003634    1
  has-miR-4322       −3.210969     down    0.004135    2
  hsa-miR-3613-3p    −7.927916     down    0.007895    3
  hsa-miR-8071       −5.435439     down    0.011404    4
  hsa-miR-6781-5p    −2.184829     down    0.012155    5
  hsa-miR-1306-3p    −2.785553     down    0.013158    6
  hsa-miR-197-5p     −3.079638     down    0.013659    7
  hsa-miR-3648       −2.732113     down    0.01416     8
  hsa-miR-6790-5p    −2.870511     down    0.014411    9
  hsa-miR-6510-5p    −3.247119     down    0.015163    10
  hsa-miR-3180-3p    −3.867019     down    0.015664    11
  hsa-miR-483-5p     −3.268119     down    0.017168    12
  hsa-miR-4481       −3.081376     down    0.017669    13
  hsa-miR-1275       −7.679397     down    0.01817     14
  hsa-miR-671-5p     −2.858979     down    0.018922    15
  hsa-miR-6856-5p    −2.697207     down    0.019173    16
  hsa-miR-6808-5p    −3.600177     down    0.019674    17
  hsa-miR-4417       −2.340955     down    0.019925    18
  hsa-miR-3162-5p    −2.315872     down    0.021429    19
  hsa-miR-4253       −5.996269     down    0.02218     20
  hsa-miR-4649-5p    −8.082261     down    0.022682    21
  hsa-miR-6782-5p    −5.188365     down    0.022932    22
  hsa-miR-6824-5p    −5.532658     down    0.023183    23
  hsa-miR-3149       −1.644625     down    0.023935    24
  hsa-miR-6716-5p    −9.950737     down    0.024937    25
  hsa-miR-5196-5p    −3.784796     down    0.026441    26
  hsa-miR-150-3p     −3.011115     down    0.028195    27
  hsa-miR-1183       −2.37409      down    0.028195    28
  hsa-miR-4689       −7.814024     down    0.028446    29
  hsa-miR-6124       −2.04976      down    0.028697    30
  hsa-miR-7150       −5.826567     down    0.029198    31
  hsa-miR-939-5p     −5.391403     down    0.029669    32
  hsa-miR-6819-5p    −4.27274      down    0.030201    33
  hsa-miR-4443       −15.229739    down    0.031955    34
  hsa-miR-6891-5p    −4.862422     down    0.032957    35
  hsa-miR-6827-5p    −1.589722     down    0.034712    36
  hsa-miR-6802-5p    −5.038429     down    0.05714     37
  hsa-miR-1909-3p    −4.403976     down    0.035965    38
  hsa-miR-3613-5p    11.28126      up      0.036967    39
  hsa-miR-4721       −1.753045     down    0.037218    40
  hsa-miR-4462       −2.61099      down    0.038972    41
  hsa-miR-7114-5p    −2.929565     down    0.040727    42
  hsa-miR-4656       −2.432757     down    0.041479    43
  hsa-miR-6871-5p    −2.100326     down    0.042481    44
  hsa-miR-6794-5p    −4.753529     down    0.044236    45
  hsa-miR-6511b-5p   1.744463      up      0.045739    46
  hsa-miR-6798-5p    −7.536286     down    0.046241    47
  hsa-miR-4298       −2.570175     down    0.046742    48
  hsa-miR-6799-5p    −3.278097     down    0.046992    49
  hsa-miR-1307-3p    −2.54687      down    0.047744    50

![Microarray assay of exosomal miRNAs differentially expressed in the plasma from mTLE-HS patients and healthy controls\
(**A**) Heat map showing the differencial expression of exosomal miRNAs in mTLE-HS patients compared to normal healthy controls. Each column represents an individual sample and each row represents a single miRNA. Expression level of each miRNA in a single sample is depicted according to the color scale. Red represents high expression, whereas green represents low expression. (**B**) The volcano plot shows the relation between the logarithm of the *p*-values on the x-axis and the log fold change between mTLE-HS patients and healthy controls on the y-axis. The vertical line marks the border between mTLE-HS patients and healthy control results. Red represents miRNAs with expression changes of more than 1.2 fold from the remaining miRNAs, while blue represents miRNAs with expression changes of less than 1.2 fold from the remaining miRNAs.](oncotarget-08-4136-g001){#F1}

QRT-PCR verification of exosomal miRNAs expression {#s2_2}
--------------------------------------------------

To validate the accuracy of the microarray based miRNA measurements, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) assays was performed. Expression levels of the 6 miRNAs selected from the miRNAs chip were determined in a cohort of 40 mTLE-HS patients and 40 healthy controls ([Supplementary Table S1](#SD1){ref-type="supplementary-material"} and [Supplementary Table S2](#SD1){ref-type="supplementary-material"}). Among these selected miRNAs, the results showed that expression levels of exosomal miRNAs (miR-4668-5P, miR-4322, miR-8071, miR-6781-5P, and miR-197-5p) were significantly decreased in the mTLE-HS patients (Figure [2](#F2){ref-type="fig"}), and the expression lever of (miR-3613-5p) was significantly increased (Figure [2](#F2){ref-type="fig"}). The qRT-PCR results were consistent with the microarray data. The results suggested that the data obtained from the miRNA microarrays accurately reflected the exosomal miRNA expression levels in the plasma from the mTLE-HS patients compared with the healthy controls.

![Validation of differential exosomal miRNAs by qRT-PCR in mTLE-HS and healthy control groups\
The results showed the relative expression levels of miR-4668-5P, miR-4322, miR-8071, miR-6781, miR-197-5p, and miR-3613-5p in 40 mTLE-HS patients and 40 healthy controls. Cel-miR-39-3p was used as a reference gene. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.](oncotarget-08-4136-g002){#F2}

Bioinformatics prediction revealed the role of exosomal miRNAs in mTLE-HS {#s2_3}
-------------------------------------------------------------------------

To assess the potential biological function of the differentially expressed miRNAs, GO annotations and KEGG pathway enrichment analysis were performed, based on three available databases (microRNA, miRBase, and TargetScan). The primary GO terms of the predicted target genes for differentially expressed miRNAs mainly included biological processes, cellular components, and molecular functions. Gene-term enrichment analysis revealed that most predicted target genes were involved in homophilic cell adhesion, synaptic transmission, signal transduction, cell adhesion, negative regulation of transcription from RNA polymer, positive regulation of transcription from RNA polymeras, protein phosphorylation, apoptotic processes (GO biological process) (Figure [3A](#F3){ref-type="fig"}), calmodulin binding, protein domain specific binding, chromatin binding, transcription corepressor activity, actin binding (Figure [3B](#F3){ref-type="fig"}), dendrites, synapses, postsynaptic density, postsynaptic membrane, and cell surface (GO cellular component) (Figure [3C](#F3){ref-type="fig"}). The KEGG pathway analysis showed that the predicted target genes were involved in biological pathways including axon guidance, pathways in cancer, regulation of the actin cytoskeleton, focal adhesion, the calcium signaling pathway, the MAPK signaling pathway, and the PI3K-Akt signaling pathway (Figure [3D](#F3){ref-type="fig"}). To further illustrate the relationship between the overlap of miRNAs and their targeted genes, the miRNA-mRNA network was generated (Figure [4](#F4){ref-type="fig"}), based on the GO and the KEGG predicted data (see above). The results suggested that differentially expressed exosomal miRNAs were involved in a wide variety of physiological processes in the development of mTLE-HS.

![Prediction of functions and signal pathways of differential exosomal miRNAs\
GO categories and distribution for the predicted miRNA targets related differential miRNAs The GO terms and signal pathways terms were sorted by enrichment scores of genes in ascending order from top to bottom. (**A**) Biological processes are enriched in signaling transduction, regulation of transcription, multicellular organismal development, cell adhesion, and ion transport. (**B**) Cellular components are enriched in the nucleus, cytoplasm, and membrane. (**C**) Molecular functions are enriched in protein binding, metal ion binding, and zinc ion binding (**D**) Pathway analysis based on potential target genes of differential miRNAs The results show the significant pathways targeted by differential miRNAs. which are rich in axon guidance, pathways in cancer, regulation of actin cytoskeleton, focal adhesion, the calcium signaling pathway, the MAPK signaling pathway, and the PI3K-Akt signaling pathway.](oncotarget-08-4136-g003){#F3}

![MiRNA-gene network\
The gray circle represents gene (mRNA), the square represents miRNA (the red marker represents up-regulated miRNA and blue marker represents down-regulated miRNA). The relationship between the miRNA and gene is represented by a green line.](oncotarget-08-4136-g004){#F4}

Evaluation of exosomal miRNAs as potential diagnostic markers {#s2_4}
-------------------------------------------------------------

To evaluate the value of exosomal miRNA levels in discriminating cases of mTLE-HS from healthy controls, ROC curve analysis was performed. Comparing the mTLE-HS and control groups, as shown in Figure [5](#F5){ref-type="fig"} and Table [2](#T2){ref-type="table"}, the ROC curve areas for miR-3613-5p, miR-4668-5p, miR-8071, and miR-197-5p were found to be 0.8444 (95% CI, 0.7402--0.9487), 0.7894 (95% CI, 0.6732--0.9057), 0.9316 (95% CI, 0.8768--0.9955), and 0.8017 (0.6881--0.9152 (Figure [5](#F5){ref-type="fig"}), respectively. The AUC for the other two miRNAs (miR-4322 and miR- 6781-5p) were \> 0.7 but did not reach statistical significance (Figure [5](#F5){ref-type="fig"} and Table [2](#T2){ref-type="table"}). More importantly, the results showed that miR-8071 was the most valuable biomarker for discriminating patients from healthy individuals, and the best cutoff of miR-8071 was 0.4500 with sensitivity and specificity of 83.33% and 96.67%, respectively. These data demonstrated that exosomal miRNAs in plasma are reliable diagnostic markers for mTLE-HS.

![ROC curves for miRNAs that are significantly different in mTLE-HS patients as compared to healthy controls\
ROC curves for exosomal miR-4668-5P, miR-4322, miR-8071, miR-6781, miR-197-5p, and miR-3613-5p were used to discriminated mTLE-HS patients and healthy controls and the area under the curve (AUC) was used to evaluate the level of discrimination.](oncotarget-08-4136-g005){#F5}

###### Area under the receiver operating characteristic curve (AUC), 95% confidence interval (CI), and *P* values of the differentially expressed microRNAs

  Exomal- miRNAs   AUC      95% CI           *P* value
  ---------------- -------- ---------------- -----------
  miR-3613-5p      0.8444   0.7402--0.9487   0.0121
  miR-4668-5P      0.7894   0.6732--0.9057   0.0363
  miR-4322         0.7144   0.5817--0.8472   0.0634
  miR-8071         0.9316   0.8768--0.9955   0.0286
  miR-197-5P       0.8017   0.6881--0.9152   0.0052
  miR-6781-5P      0.7811   0.6585--0.9037   0.0743

Correlation between exosomal miRNAs and clinical characteristics {#s2_5}
----------------------------------------------------------------

The above results suggested that exosomal miRNAs are good diagnostic biomarkers of mTLE-HS. We further analyzed the association between exosomal miR-8071 expression and clinicopathological characteristics in mTLE-HS patients. The expression levels of exosomal miR-8071 were categorized as low or high in relation to the median value. Our results demonstrated that there was no significant correlation between exosomal miR-8071 expression and clinicopathological features, such as age, gender, family history of epilepsy, seizure time, laterality of the epileptogenic zone, AED therapy at the last clinic visit, sampling time from the last seizure, and comorbid conditions (Table [3](#T3){ref-type="table"}). However, we found that the exosomal miR-8071 level was significantly associated with disease duration or seizure frequency (Table [3](#T3){ref-type="table"}). These results indicated that exosomal miRNAs were involved in the epileptogenesis of mTLE-HS.

###### Demographic and clinical data of patients with mTLE-HS

  Characteristic                                Exosmal miR-8071 expression   *P*                      
  --------------------------------------------- ----------------------------- ------------------------ ----------
  Male: Female                                  12:8                          13:7                     0.1257
  Age (range)                                   26.21 years (11--38)          28.32 years (15--49)     0.0630
  Family history of epilepsy                    1 (5%)                        3 (17%)                  0.0720
  Course of epilepsy (range)                    10.05 years (1--28)           17.41 years (1--26)      0.0073\*
  Onset of seizure (range)                      18.06 years (2--30)           12.38 years (0.5--29)    0.0661
  Seizure frequency (range)(months)             28.60 (1--300)                81.20 (1--330)           0.0316\*
  Seizure time (range)                          1.55 min (5 s--5 min)         2.20 min (2 s--10 min)   0.0680
  Laterality of epileptogenic zone                                                                     
   Right                                        8 (40%)                       7 (35%)                  0.2926
   Left                                         10 (50%)                      13 (65%)                 
   Bilateral                                    2 (10%)                       0 (0%)                   
  Sampling time from the last seizure (range)   5.80 (1--28)                  6.52 (3--30)             0.0875
  AED therapy at the last clinic visit                                                                 
   Valproic acid                                15                            10                       0.8600
   Carbamazepine                                18                            17                       
   Levetirasetam                                8                             12                       
   Oxcarbazepine                                12                            14                       
   Lamotrigine                                  6                             4                        
   Topiramate                                   3                             3                        
   Others                                       2                             3                        
  Comorbid conditions                                                                                  
   Hypertension                                 2                             1                        0.3910
   Diabetes                                     1                             1                        
   Hyperlipidemia                               1                             1                        
   Others                                       0                             0                        

DISCUSSION {#s3}
==========

Recently, numerous studies have shown that exosomal miRNAs were involved in pathophysiology of diseases, especially in cancer, neurodegenerative diseases, and infection \[[@R8], [@R12], [@R13]\]. However, the previous studies of mTLE-HS have focused on animals or circulating miRNAs, and were seldom related to exosomal miRNAs \[[@R1], [@R15]\]. In the present study, our results showed a differential exosomal miRNAs expression profile in plasma from mTLE-HS patients compared with healthy controls.

Epileptogenesis is thought to be involved in several processes, such as neuronal loss, gliosis, gene regulation, axonal sprouting, inflammation, and neurogenesis \[[@R16]--[@R18]\]. MiRNAs often suppressed expression of multiple proteins by inhibiting translation or targeting mRNAs at 3′UTR for degradation \[[@R19]\]. According the previous reports, current bioinformatics tools for miRNA-target analysis were widely used in studying association between miRNAs and diseases, including cancer, inflammation, neurodegenerative diseases and epilepsy \[[@R12], [@R13], [@R15], [@R20]\]. These studies indicated these miRNA target prediction tools were effective and accuracy for miRNA target prediction. We further investigated the possible functions of miRNAs through GO terms and KEGG pathway annotation, based on bioinformatics tools. Our results suggested that cell adherence, the cell cycle, and apoptosis were significant GO categories affected by these dysregulated miRNAs. More importantly, these biological processes may also contribute to epileptogenesis. For example, as previously reported, cell apoptosis can cause hippocampal neuronal loss after epileptic seizures \[[@R15]\].

The KEGG is widely used for analysis of various types of molecular biological data in order to discover signaling pathways \[[@R21]\]. Our results showed that many signaling pathways were, as identified by KEGG pathway annotation, affected by these dysregulated microRNAs, such as axon guidance, pathways in cancer, regulation of the actin cytoskeleton, focal adhesion, the calcium signaling pathway, the MAPK signaling pathway, and the PI3K-Akt signaling pathway. As previously reported, axon guidance has been linked to epilepsy, with the sprouting of mossy fibers (the axons of granule cells) being the best characterization of axonal reorganization in TLE \[[@R22]\]. The neurotrophin receptor-interacting factor (NRIF) mediates apoptotic signaling via p75(NTR) in hippocampal neurons *in vitro* and *in vivo* \[[@R23]\]. The PI3K/Akt and ERK1/2 signaling pathways mediate the EPO-modulated calcium influx in KA-induced epilepsy \[[@R24]\]. To further investigate the function of differentially expressed exosomal miRNAs, the miRNA-mRNA regulatory network was analyzed by bioinformatic observations, and then the main targets of miRNAs were outlined (shown in Figure [5](#F5){ref-type="fig"}). These results suggested that exosomal miRNAs may have regulatory effects on the pathogenesis of epilepsy by affecting lots of biological progress and signaling pathways as mentioned above.

Currently, the diagnosis of epilepsy mainly depends on the complaint, CT, MRI, and EEG, which can be inaccurate and costly. Exploring biomarkers which could distinguish between epileptic and healthy individual is required. Compared to mRNAs and even proteins, miRNAs are in a relatively stable form, which makes miRNAs potential candidates as noninvasive biomarkers \[[@R25]\]. Some preclinical studies on epilepsy offer the exciting possibility of miRNAs acting as biomarkers for disease diagnosis, stratification, and monitoring \[[@R1]\]. In our study, in order to evaluate the efficiency of these miRNAs for diagnosing mTLE-HS, ROC curves were constructed for each miRNA. ROC curves for four miRNAs (miR-3613-5p, miR-4668-5p, miR-8071, and miR-197-5p) showed good ability to efficiently distinguish mTLE-HS patients from healthy control, with an AUC that ranged from 0.6482 to 0.9955. These results indicated that exosomal miRNAs could be used as better biomarker of diagnosis of mTLE-HS. It would be interesting to determine the relation between exosomal miRNAs and clinical parameters. More importantly, we proved that exosomal miR-8071 expression was significantly associated with seizure severity of patients with mTLE-HS. Thus, these results indicated that exosomal miRNAs were involved in the progression of mTLE-HS. However, we need to further study the function mechanism of exosomal miRNAs on epileptogenesis. In addition, interestingly enough, the exosome could be released from kinds of organs, including muscles, liver, blood cells, and brain tissues \[[@R26]--[@R29]\]. Due to the complexity of mTLE-HS in pathogenesis and treatment, now, it is not clear that which organs exosomal miRNAs are from. This requires that we continue making great efforts and studying further.

In conclusion, the present study is the first to evaluate the plasma miRNA expression pattern in mTLE-HS patients by microarray-based miRNA analysis. Functional bioinformatics analysis demonstrated that the target genes regulated by these miRNAs were involved in several biological processes and signaling pathways. Expression levels of exosomal miRNAs (miR-3613-5p, miR-4668-5p, miR-8071, and miR-197-5p) showed good ability to efficiently distinguish mTLE-HS patients from healthy controls. The study of these miRNAs may provide a clearer understanding on the pathogenesis of mTLE-HS and indicate that exosomal miRNAs may be used as potential therapeutic targets and diagnostic biomarkers for mTLE-HS.

MATERIALS AND METHODS {#s4}
=====================

Plasma collection {#s4_1}
-----------------

In this study, 40 patients diagnosed with mTLE-HS and gender and age matched 40 healthy volunteers were recruited in the Tiantan Hospital (Beijing, China). 40 patients were referred for surgical resection of the temporal lobe by an epileptologist following extensive evaluation including neurological assessment, video EEG recording, and MRI neuroimaging \[[@R30], [@R31]\]. Each patient was determined to have medically intractable epilepsy with a history of recurring seizures, and hippocampal sclerosis was confirmed by postoperative pathology. A 5 ml sample of venous blood was collected from each patient diagnosed mTLE-HS, and a 5 ml sample of venous blood from gender and age matched healthy volunteers as the control group. Blood samples were drawn into EDTA-containing tubes and the plasma was immediately separated using a centrifuge at room temperature (centrifugation at 2,500 × g for 10 min). The supernatant was then transferred into RNase-free EP tubes and stored at −80°C until use. This study was approved by the Research Ethics Committee of Tiantan Hospital (Beijing, China) and informed consent was given by each subject.

Isolation of exosomes {#s4_2}
---------------------

Exosomes were isolated from the plasma of the patient and healthy control groups by exoquick precipitation (RIBO, Guangzhou, China) according manufacturer\'s instructions \[[@R32]\]. After the cold plasma was thawed at 4°C, the plasma was subjected to successive centrifugations of 2,000 × g (20 min) and 10,000 × g (20 min). Then, the plasma was transferred into new EP tubes and the mixed reagent was added to the plasma and placed at 4°C for 30 min. Exosomes pellets were centrifuged to remove the supernatant at 10,000g for 30 min and the exosomes were identified by transmission electron microscopy (TEM) or Western blot analysis (not shown).

RNA processing and miRNA profiling {#s4_3}
----------------------------------

Exosomal RNA was extracted using trizol reagent (Life Technologies, Carlsbad, CA, USA) according to the manufacturer\'s instructions. RNA quality and quantity was measured according to the OD260/280 using a Nanodrop ND-1000 system (Thermo Fisher Scientific, Waltham, USA). The exosomes from plasma of three mTLE-HS patients and three healthy volunteers were investigated by miRNA microarray analysis. Exosomal miRNAs were extended and hybridized with fluorescence labeled with biotin dyes on a Gene Chip miRNA 4.0 Array (Affymetrix, Cleveland, OH, USA). Following hybridization, the images were digitized and analyzed using a laser scanner interfaced with ArrayPro image analysis software (Media Cybernetics, Silver Spring, MD, USA). Data were analyzed by first subtracting the background and then the signals were normalized using a LOWESS filter (Locally-weighted Regression) \[[@R33]\] The differentially expressed miRNAs were defined using the ratio of detected signals log2-fold changes \[log2(mTLE-HS/control)\] and the Student\'s *t-test* was used to calculate *P* values. Those with a log2 ratio \> 1.2. or ≤ −1.2 and *P* values \< 0.05 were considered as differentially expressed miRNAs. Cluster analysis based on the relative expression levels of miRNAs was also carried out.

QPCR miRNA assay for individual miRNAs {#s4_4}
--------------------------------------

To validate the initial results of the miRNA microarray assay, qRT-PCR analyses were carried out using the Thermal Cycler Dice (TAKALA, Hercules, CA). Five down-regulated miRNAs (miR-4668-5P, miR-4322, miR-8071, miR-6781, and miR-197-5p) and one up-regulated (miR-3613-5p) were selected for subsequent qRT-PCR confirmation. The primers of miRNAs were purchased from RIBO (Guangzhou, China). Real-time PCR for miRNAs was performed according to previous reports in triplicate for each sample \[[@R20]\]. The relative amount of each miRNA was normalized against cel-miR-39-3p by the 2 ^−ΔΔCt^ method.

Bioinformatics analysis of differentially expressed exosomal miRNAs {#s4_5}
-------------------------------------------------------------------

The target genes of differentially exosomal miRNAs were predicted by TargetScan (<http://www.targetscan.org/>) microRNA ([http:/www.microrna.org/microrna/home.do](http://www.impactjournals.com/www.microrna.org/microrna/home.do)) and miRBase ([http://www.mirbase.org](http://www.mirbase.org/)) \[[@R20]\]. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) database analyses were performed by a DAVID online analysis tool (<http://david.abcc.ncifcrf.gov/>) \[[@R34], [@R35]\]. Fisher\'s two-side exact test and Chi-square test were used to classify the GO categories and KEGG pathway categories, and the false discovery rate (FDR) was also calculated to correct the *P* values. We chose only GOs and the enriched pathways that had a *P value* of \< 0.05 and a FDR of \< 0.05. The relationship between miRNAs and genes was counted by their differential expression values and according to their interactions in the Sanger miRNA database. The miRNA-mRNA networks were generated by Gene-Cloud of Biotechnology Information (GCBI) (<https://www.gcbi.com.cn/gclib/html/index>).

Statistical analysis {#s4_6}
--------------------

All statistical analysis was performed using the SPSS 17.0 statistical software (SPSS Inc., Chicago, IL, USA) or Graphpad Prism (version 5.0; Graphpad software). The difference between two groups was determined by a two-tailed Student\'s *t* test. Receiver Operator Characteristic (ROC) curves and area under the ROC curve (AUC) were established to evaluate the diagnostic value of exosome miRNAs for differentiating between mTLE-HS and healthy control groups. Clinical characteristics were compared using the χ2 test of independence for qualitative variables, ANOVA or *t-test* of quantitative variables with normal distribution, the non-parametric Kruskall-Wallis test or the Mann-Whitney *U* test of quantitative variables with skewed distribution, with *P* values of \< 0.05 considered to be statistically significant.

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================

This work was supported by grants from the National Natural Science Foundation of China (NO 81471315), the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding (No. ZYLX201305), the Scientific Research Common Program of Beijing Municipal Commission of Education (No. KZ201510025029), and Beijing Municipal Science & Technology Comission (No:Z161100000216130). Thanks to Dr, Edward C. Mignot, Shandong University, for linguistic advice.

**CONFLICTS OF INTEREST**

All the authors declare that there was no conflicts of interest.

mTLE-HS

:   mesial temporal lobe epilepsy (mTLE) with hippocampal sclerosis (HS)

AUC

:   area under the receiver operating characteristic curve

CI

:   confidence interval

GO

:   The Gene Ontology (GO)

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

PCa

:   prostate cancer

AUC

:   area under the receiver operating characteristic curve

CI

:   confidence interval

qRT-PCR

:   quantitative reverse transcriptase polymerase chain reaction

GCBI

:   Gene-Cloud of Biotechnology Information

microRNAs

:   miRNAs
